MODERNA INC. DL-,0001 WKN: A2N9D9 ISIN: US60770K1079 Forum: Aktien Thema: Hauptdiskussion

Nicht nur Citi

Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell. By Mackenzie Tatananni Updated Sept 30, 2026, 9:58 am EDT / Original Sept 30, 2026, 7:42 am EDT 'He added that he struggles to justify Moderna’s current valuation whether comparing it to public peers or calculating the net present value of its product pipeline. With a market value near $80 billion, Moderna is valued similarly to Regeneron despite delivering materially lower expected revenue and earnings. The share move demands more from intismeran, Meacham added. While the latest trial met its main goal, the detailed numbers remain undisclosed. Typical for top-line results, the announcement merely noted that a treatment combining intismeran with Merck’s Keytruda was more effective at preventing the recurrence of skin cancer than Keytruda alone. The next stock catalyst could be the annual meeting of the European Society for Medical Oncology in late October, where Moderna is set to provide more details on its intismeran program. Meacham views a recurrence-free survival hazard ratio of roughly 0.72 as “clinical credible” and 0.65 or lower as “a clear win.” The figure represents the risk of cancer returning in a treatment group compared to a control group over time. Still, Meacham believes the recent stock surge raises the bar, meaning a hazard ratio of 0.72 might qualify for regulatory approval but still leave investors questioning commercial prospects if other clinical metrics are soft. Currently, the data don’t justify Moderna’s valuation, as success in melanoma—where intismeran showed promising results—doesn’t broadly validate the platform, given that skin cancer is relatively easy to treat. Lung, kidney, and bladder cancers are biologically quite different, meaning success in those trials is far from guaranteed. Moderna is evaluating intismeran across nine trials in various solid tumors. In just a few weeks, the drugmaker will present Phase 3 data evaluating intismeran in combination with immunotherapy for early-stage non-small cell lung cancer. However, Meacham cautioned that regulatory approval—which optimistic estimates suggest is still months away—will be the easy part. To justify Moderna’s steep valuation, late-stage trials must show a clinical benefit large enough to offset the high cost of manufacturing bespoke vaccines for a broader population.'

Und Aktion

Die wollen euer Geld

Ja ich hoffe 👍

Das Ding geht gleich wieder hoch ich denke nicht das die amis den shortern das Spielfeld überlassen . Lassen wir uns eines besseren belehren

Runter muss der Bums

Nur wegen Citi??

Boah was für ein Dilemma 🤔

Da ist noch viel Luft nach unten

Short läuft

Weil?

Endlich geht das ding runter drr hebel hat sich gelohnt haha

Wird heute wieder grün

Gemini: Citigroup downgraded Moderna (MRNA) from Neutral to Sell on September 30, 2026. 📉 Citi's Rating Action • New Rating: Sell (down from Neutral). • Price Target: Raised to $80 from $60. • Implied Downside: Suggests a potential steep pullback from recent trading peaks. ⚠️ Key Rationale • Stretched Valuation: Shares surged too fast since mid-August. • Rich Pricing: Multiples look high compared to biotech peers like Regeneron. • Commercial Lag: Near-term earnings lag behind market hype for cancer vaccines.

Die Amis kaufen sich heute günstig ein. Es wird bis zum 24.10. ständig hoch und runter gehen weil jeder versucht sich günstig einzudecken um dann den größtmöglichen Erfolg zu erzielen